Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1134238.RArU3nKqsqfkEhyp5I8gXA2BlGbtmGlAz9tAG-exNz6rc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1134238.RArU3nKqsqfkEhyp5I8gXA2BlGbtmGlAz9tAG-exNz6rc130_assertion type Assertion NP1134238.RArU3nKqsqfkEhyp5I8gXA2BlGbtmGlAz9tAG-exNz6rc130_head.
- NP1134238.RArU3nKqsqfkEhyp5I8gXA2BlGbtmGlAz9tAG-exNz6rc130_assertion description "[In biliary tract cancer, reported BRAF mutation rates are highly controversial, ranging from 0 to 33% in adenocarcinoma of the gallbladder and 0 to 22% in cholangiocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1134238.RArU3nKqsqfkEhyp5I8gXA2BlGbtmGlAz9tAG-exNz6rc130_provenance.
- NP1134238.RArU3nKqsqfkEhyp5I8gXA2BlGbtmGlAz9tAG-exNz6rc130_assertion evidence source_evidence_literature NP1134238.RArU3nKqsqfkEhyp5I8gXA2BlGbtmGlAz9tAG-exNz6rc130_provenance.
- NP1134238.RArU3nKqsqfkEhyp5I8gXA2BlGbtmGlAz9tAG-exNz6rc130_assertion SIO_000772 24309328 NP1134238.RArU3nKqsqfkEhyp5I8gXA2BlGbtmGlAz9tAG-exNz6rc130_provenance.
- NP1134238.RArU3nKqsqfkEhyp5I8gXA2BlGbtmGlAz9tAG-exNz6rc130_assertion wasDerivedFrom befree-2016 NP1134238.RArU3nKqsqfkEhyp5I8gXA2BlGbtmGlAz9tAG-exNz6rc130_provenance.
- NP1134238.RArU3nKqsqfkEhyp5I8gXA2BlGbtmGlAz9tAG-exNz6rc130_assertion wasGeneratedBy ECO_0000203 NP1134238.RArU3nKqsqfkEhyp5I8gXA2BlGbtmGlAz9tAG-exNz6rc130_provenance.